Trial reportHIV medicine2026
Exploring the impact of baseline and on-treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study.
Trial report in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A French National Real-World Survey of People With Multiresistant HIV-1 Viruses Receiving an Antiretroviral Regimen Including Fostemsavir or Ibalizumab.Open forum infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesThe gp120-directed attachment inhibitor fostemsavir was effective in people with multidrug-resistant (MDR) HIV-1 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and identify individuals for fostemsavir-based regimens. In previous multivariable analyses, baseline CD4+ T-cell count, baseline log
methodsBRIGHTE participant data (Randomized Cohort [RC], n = 272; Non-randomized Cohort, n = 99) were evaluated to examine baseline factors associated with virologic outcomes (HIV-1 RNA <40 copies/mL [Snapshot]; protocol-defined virologic failure [PDVF]) using linear/logistic regression with stepwise selection. A separate analysis evaluated baseline factors for association with treatment-adherent PDVF.
resultsIn RC participants, higher baseline log
conclusionsMultivariable analysis (MVA) identified several factors predictive of virologic response. No baseline factors were highly predictive of virologic failure at Weeks 96 or 192. Findings support the use of fostemsavir in diverse populations with MDR HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.